INR 156.86
(2.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 51.18 Million INR | -80.22% |
2022 | 460.47 Million INR | 27.54% |
2021 | 361.04 Million INR | 27.0% |
2020 | 284.27 Million INR | 14.17% |
2019 | 249 Million INR | 14.81% |
2018 | 216.88 Million INR | -10.99% |
2017 | 243.64 Million INR | 73.78% |
2016 | 140.2 Million INR | 6.46% |
2015 | 131.7 Million INR | -8.77% |
2014 | 144.36 Million INR | -2.46% |
2013 | 148 Million INR | 37.29% |
2012 | 107.8 Million INR | 38.9% |
2011 | 77.61 Million INR | 96.74% |
2010 | 39.45 Million INR | 28.58% |
2009 | 30.68 Million INR | 12.38% |
2008 | 27.3 Million INR | 8.01% |
2007 | 25.27 Million INR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 22.74 Million INR | 139.87% |
2023 Q3 | 56.26 Million INR | 0.84% |
2023 FY | 91.09 Million INR | -80.22% |
2023 Q2 | 55.79 Million INR | 190.03% |
2023 Q1 | 19.23 Million INR | -61.27% |
2023 Q4 | 23.46 Million INR | -58.31% |
2022 Q2 | 148.49 Million INR | 28.61% |
2022 Q4 | 49.67 Million INR | -66.17% |
2022 Q1 | 115.45 Million INR | 586.27% |
2022 FY | 460.47 Million INR | 27.54% |
2022 Q3 | 146.84 Million INR | -1.11% |
2021 Q1 | 102.85 Million INR | 185.58% |
2021 Q2 | 116.28 Million INR | 13.06% |
2021 Q3 | 125.08 Million INR | 7.57% |
2021 Q4 | 16.82 Million INR | -86.55% |
2021 FY | 361.04 Million INR | 27.0% |
2020 Q3 | 89.54 Million INR | 1.86% |
2020 Q4 | 36.01 Million INR | -59.78% |
2020 Q2 | 87.91 Million INR | 24.18% |
2020 Q1 | 70.79 Million INR | 765.94% |
2020 FY | 284.27 Million INR | 14.17% |
2019 Q3 | 87.18 Million INR | 10.45% |
2019 FY | 249 Million INR | 14.81% |
2019 Q2 | 78.93 Million INR | 5.67% |
2019 Q1 | 74.7 Million INR | 1010.65% |
2019 Q4 | 8.17 Million INR | -90.62% |
2018 Q2 | 74.98 Million INR | 1.41% |
2018 Q4 | -8.2 Million INR | -110.7% |
2018 FY | 216.88 Million INR | -10.99% |
2018 Q1 | 73.94 Million INR | -13.55% |
2018 Q3 | 76.63 Million INR | 2.2% |
2017 Q2 | 76.24 Million INR | 6.14% |
2017 FY | 243.64 Million INR | 73.78% |
2017 Q4 | 85.52 Million INR | 4.46% |
2017 Q3 | 81.87 Million INR | 7.39% |
2017 Q1 | 71.83 Million INR | 47.45% |
2016 Q1 | 38.91 Million INR | -8.13% |
2016 Q4 | 48.71 Million INR | 23.55% |
2016 Q3 | 39.43 Million INR | -39.03% |
2016 Q2 | 64.67 Million INR | 66.19% |
2016 FY | 140.2 Million INR | 6.46% |
2015 Q3 | 38.69 Million INR | -5.73% |
2015 Q4 | 42.36 Million INR | 9.49% |
2015 Q1 | 33.72 Million INR | 20.24% |
2015 Q2 | 41.04 Million INR | 21.69% |
2015 FY | 131.7 Million INR | -8.77% |
2014 Q4 | 28.04 Million INR | -36.71% |
2014 FY | 144.36 Million INR | -2.46% |
2014 Q1 | 25.5 Million INR | 591.31% |
2014 Q2 | 46.49 Million INR | 82.3% |
2014 Q3 | 44.31 Million INR | -4.68% |
2013 Q1 | 44 Million INR | 151.36% |
2013 Q3 | 47.5 Million INR | -23.01% |
2013 Q4 | -5.19 Million INR | -110.93% |
2013 FY | 148 Million INR | 37.29% |
2013 Q2 | 61.7 Million INR | 40.23% |
2012 Q1 | 17.9 Million INR | -4.85% |
2012 Q2 | 32.2 Million INR | 79.89% |
2012 Q3 | 40.2 Million INR | 24.84% |
2012 FY | 107.8 Million INR | 38.9% |
2012 Q4 | 17.5 Million INR | -56.46% |
2011 Q3 | 22.8 Million INR | 16.92% |
2011 Q2 | 19.5 Million INR | 0.0% |
2011 FY | 77.61 Million INR | 96.74% |
2011 Q4 | 18.81 Million INR | -17.49% |
2010 FY | 39.45 Million INR | 28.58% |
2009 FY | 30.68 Million INR | 12.38% |
2008 FY | 27.3 Million INR | 8.01% |
2007 FY | 25.27 Million INR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Sigachi Industries Limited | 579.88 Million INR | 91.174% |
Ind-Swift Limited | 946.56 Million INR | 94.593% |
Bajaj HealthCare Limited | 985.34 Million INR | 94.806% |
Sakar Healthcare Limited | 204.07 Million INR | 74.921% |
Aurobindo Pharma Limited | 55.65 Billion INR | 99.908% |
Innova Captab Limited | 931.03 Million INR | 94.503% |
Divi's Laboratories Limited | 14.17 Billion INR | 99.639% |
AstraZeneca Pharma India Limited | 2.47 Billion INR | 97.931% |
Morepen Laboratories Limited | 1.98 Billion INR | 97.425% |
Mankind Pharma Limited | 29.27 Billion INR | 99.825% |
Sequent Scientific Limited | 2.9 Billion INR | 98.236% |
Wanbury Limited | 978.96 Million INR | 94.772% |
Laurus Labs Limited | 11.9 Billion INR | 99.57% |
Nectar Lifesciences Limited | 932.7 Million INR | 94.513% |
Glenmark Life Sciences Limited | 11.64 Billion INR | 99.56% |
Alembic Limited | 872.45 Million INR | 94.134% |
Hikal Limited | 4.46 Billion INR | 98.853% |
Alembic Pharmaceuticals Limited | 15.86 Billion INR | 99.677% |
Neuland Laboratories Limited | 2.92 Billion INR | 98.253% |
J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 99.654% |
Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 99.891% |
IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | 97.675% |
Themis Medicare Limited | 1.12 Billion INR | 95.454% |
RPG Life Sciences Limited | 1.63 Billion INR | 96.871% |
Zydus Lifesciences Limited | 125.21 Billion INR | 99.959% |
Lupin Limited | 125.09 Billion INR | 99.959% |
Amrutanjan Health Care Limited | 2.09 Billion INR | 97.556% |
Wockhardt Limited | 8.48 Billion INR | 99.396% |
Vaishali Pharma Limited | 84.02 Million INR | 39.092% |
Aarti Pharmalabs Limited | 3.07 Billion INR | 98.335% |
Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | 88.33% |
Jubilant Pharmova Limited | 14.45 Billion INR | 99.646% |
FDC Limited | 3.49 Billion INR | 98.538% |
Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 99.947% |
Kilitch Drugs (India) Limited | 412.42 Million INR | 87.591% |
Eris Lifesciences Limited | 4.94 Billion INR | 98.965% |
Venus Remedies Limited | 1.91 Billion INR | 97.329% |
ZIM Laboratories Limited | 1.01 Billion INR | 94.948% |
Bliss GVS Pharma Limited | 1.41 Billion INR | 96.394% |
Par Drugs and Chemicals Limited | 58.28 Million INR | 12.195% |
Caplin Point Laboratories Limited | 2.17 Billion INR | 97.646% |
Shilpa Medicare Limited | 3.33 Billion INR | 98.465% |
Albert David Limited | 1.02 Billion INR | 95.012% |
Ajanta Pharma Limited | 30.46 Billion INR | 99.832% |
Hester Biosciences Limited | 908.84 Million INR | 94.369% |
Suven Pharmaceuticals Limited | 1.4 Billion INR | 96.352% |
Solara Active Pharma Sciences Limited | 2.55 Billion INR | 97.996% |
Gufic Biosciences Limited | 1.18 Billion INR | 95.687% |
Windlas Biotech Limited | 1 Billion INR | 94.915% |
Procter & Gamble Health Limited | 2.99 Billion INR | 98.291% |
Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -260.093% |
Mangalam Drugs & Organics Limited | 162.22 Million INR | 68.452% |
Granules India Limited | 10.31 Billion INR | 99.504% |
Aarti Drugs Limited | 1.16 Billion INR | 95.616% |
Bal Pharma Limited | 555.62 Million INR | 90.789% |
Alkem Laboratories Limited | 32.83 Billion INR | 99.844% |
Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 99.967% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | 95.235% |
Medicamen Biotech Limited | 335.16 Million INR | 84.73% |
Unichem Laboratories Limited | 6.72 Billion INR | 99.239% |
Bafna Pharmaceuticals Limited | 455.58 Million INR | 88.766% |
Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -650.44% |
Valiant Laboratories Limited | 138.02 Million INR | 62.921% |
Orchid Pharma Limited | 800.77 Million INR | 93.609% |
Medico Remedies Limited | 59.67 Million INR | 14.235% |
Ind-Swift Laboratories Limited | 2.12 Billion INR | 97.591% |
Ipca Laboratories Limited | 18.98 Billion INR | 99.73% |
Syncom Formulations (India) Limited | 345.63 Million INR | 85.192% |
Piramal Enterprises Limited | 63.65 Billion INR | 99.92% |
Torrent Pharmaceuticals Limited | 21.42 Billion INR | 99.761% |
NATCO Pharma Limited | 10.05 Billion INR | 99.491% |
Suven Life Sciences Limited | 109.75 Million INR | 53.367% |
Krebs Biochemicals & Industries Limited | 46.15 Million INR | -10.885% |
Strides Pharma Science Limited | 9.16 Billion INR | 99.441% |
Indoco Remedies Limited | 12.06 Billion INR | 99.576% |
Alpa Laboratories Limited | 127.38 Million INR | 59.821% |
Lasa Supergenerics Limited | 291.17 Million INR | 82.423% |
Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 98.337% |